You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

Details for New Drug Application (NDA): 211280


✉ Email this page to a colleague

« Back to Dashboard


NDA 211280 describes REYVOW, which is a drug marketed by Eli Lilly And Co and is included in one NDA. It is available from one supplier. There are two patents protecting this drug. Additional details are available on the REYVOW profile page.

The generic ingredient in REYVOW is lasmiditan succinate. One supplier is listed for this compound. Additional details are available on the lasmiditan succinate profile page.
Summary for 211280
Tradename:REYVOW
Applicant:Eli Lilly And Co
Ingredient:lasmiditan succinate
Patents:2
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 211280
Generic Entry Date for 211280*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Suppliers and Packaging for NDA: 211280
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
REYVOW lasmiditan succinate TABLET;ORAL 211280 NDA Eli Lilly and Company 0002-4312 0002-4312-08 2 BLISTER PACK in 1 CARTON (0002-4312-08) / 4 TABLET in 1 BLISTER PACK
REYVOW lasmiditan succinate TABLET;ORAL 211280 NDA Eli Lilly and Company 0002-4312 0002-4312-61 1 BLISTER PACK in 1 CARTON (0002-4312-61) / 4 TABLET in 1 BLISTER PACK

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 50MG BASE
Approval Date:Jan 31, 2020TE:RLD:Yes
Regulatory Exclusivity Expiration:Jan 31, 2025
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:⤷  Sign UpPatent Expiration:Dec 5, 2037Product Flag?YSubstance Flag?YDelist Request?
Patented Use:ACUTE TREATMENT OF MIGRAINE
Patent:⤷  Sign UpPatent Expiration:Feb 17, 2028Product Flag?YSubstance Flag?YDelist Request?
Patented Use:ACUTE TREATMENT OF MIGRAINE

Expired US Patents for NDA 211280

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eli Lilly And Co REYVOW lasmiditan succinate TABLET;ORAL 211280-002 Jan 31, 2020 ⤷  Sign Up ⤷  Sign Up
Eli Lilly And Co REYVOW lasmiditan succinate TABLET;ORAL 211280-001 Jan 31, 2020 ⤷  Sign Up ⤷  Sign Up
Eli Lilly And Co REYVOW lasmiditan succinate TABLET;ORAL 211280-003 Dec 18, 2020 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.